NGM Biopharmaceuticals (NYSE:NGM) Director Group L. P. Column acquired 6,425 shares of the firm’s stock in a transaction on Monday, August 17th. The stock was purchased at an average price of $17.89 per share, with a total value of $114,943.25. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
NGM stock opened at $17.90 on Tuesday. NGM Biopharmaceuticals has a 12 month low of $8.81 and a 12 month high of $23.95. The firm has a 50-day moving average of $18.84 and a two-hundred day moving average of $17.89.
NGM Biopharmaceuticals (NYSE:NGM) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.38) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.30) by ($0.08).
A number of hedge funds have recently added to or reduced their stakes in the business. Engineers Gate Manager LP raised its holdings in NGM Biopharmaceuticals by 30.2% in the 2nd quarter. Engineers Gate Manager LP now owns 57,506 shares of the company’s stock valued at $1,135,000 after acquiring an additional 13,353 shares during the last quarter. Jacobs Levy Equity Management Inc. raised its holdings in NGM Biopharmaceuticals by 44.5% in the 2nd quarter. Jacobs Levy Equity Management Inc. now owns 199,396 shares of the company’s stock valued at $3,936,000 after acquiring an additional 61,432 shares during the last quarter. Point72 Asset Management L.P. raised its holdings in NGM Biopharmaceuticals by 52.9% in the 2nd quarter. Point72 Asset Management L.P. now owns 1,523,585 shares of the company’s stock valued at $30,076,000 after acquiring an additional 527,290 shares during the last quarter. Bank of America Corp DE grew its stake in shares of NGM Biopharmaceuticals by 136.7% in the 2nd quarter. Bank of America Corp DE now owns 13,953 shares of the company’s stock valued at $275,000 after buying an additional 8,058 shares during the period. Finally, Vanguard Group Inc. grew its stake in shares of NGM Biopharmaceuticals by 197.2% in the 2nd quarter. Vanguard Group Inc. now owns 1,408,979 shares of the company’s stock valued at $27,812,000 after buying an additional 934,972 shares during the period.
A number of research analysts have weighed in on NGM shares. Raymond James upped their price objective on shares of NGM Biopharmaceuticals from $31.00 to $32.00 and gave the stock a “strong-buy” rating in a research report on Thursday, May 14th. BMO Capital Markets started coverage on shares of NGM Biopharmaceuticals in a research report on Thursday, June 4th. They set an “outperform” rating and a $30.00 price target for the company. B. Riley restated a “buy” rating and set a $30.00 price target on shares of NGM Biopharmaceuticals in a research report on Friday. Stifel Nicolaus restated a “buy” rating and set a $32.00 price target on shares of NGM Biopharmaceuticals in a research report on Monday, May 18th. Finally, Piper Sandler started coverage on shares of NGM Biopharmaceuticals in a research report on Thursday, July 30th. They set an “overweight” rating and a $30.00 price target for the company. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $29.33.
About NGM Biopharmaceuticals
NGM Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel therapeutics for the treatment of cardio-metabolic, liver, oncologic, and ophthalmic diseases. The company's product candidates include Aldafermin, an engineered variant of the FGF19 human hormone in Phase 2b clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); NGM313, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase 1b clinical trial for use in the treatment of type 2 diabetes and NASH; and NGM395, which is engineered variant of the GDF15 human hormone for use in the treatment of metabolic syndrome.
Featured Story: Systematic Risk
